

AMENDMENTS TO THE CLAIMS

This **listing of claims** will replace all prior versions, and listings, of the claims in the application.

Listing of Claims

1-144. (Canceled)

145. (Currently Amended) A method of treating a transplant recipient or preventing transplant rejection in a transplant recipient, comprising administering to the recipient an effective amount of an immunoglobulin specific to B7-1 and an effective amount of an immunoglobulin specific to B7-2, further including administering a third agent selected from the group consisting of: calcineurin inhibitor, steroid, and immunosuppressive agent that arrest the growth of immune cells, methotrexate, transplant salvage pathway inhibitor, IL-2 receptor antagonist, and analogs thereof, and wherein an inhibitor of the CD40 /or CD40 ligand costimulatory interaction is not administered to the transplant recipient.

146. (Canceled)

147. (Currently Amended) The method of Claim 145 146, wherein cyclosporin A or FK506 is administered.

148. (Canceled)

149. (Currently Amended) The method of Claim 145 146, wherein rapamycin is administered.

150. (Previously Presented) The method of Claim 145, wherein the immunoglobulin specific to B7-1 is administered in an amount between about 1 mg/kg and about 25 mg/kg, and the immunoglobulin specific to B7-2 is administered in an amount between about 1 mg/kg and about 25 mg/kg.

151. (Previously Presented) The method of Claim 150, wherein the immunoglobulin specific to B7-1 and the immunoglobulin specific to B7-2 are administered on the day the recipient receives the transplantation.

152. (Previously Presented) The method of Claim 149, wherein the humanized immunoglobulin specific to B7-1 and the humanized immunoglobulin specific to B7-2 are further administered periodically after the recipient receives the transplantation.

153. (Previously Presented) The method of Claim 152, wherein the humanized immunoglobulin specific to B7-1 is administered between about 1 mg/kg and about 5 mg/kg, and the humanized immunoglobulin specific to B7-2 is administered between about 1 mg/kg and about 5 mg/kg at least weekly after the recipient receives the transplantation.

154. (Currently Amended) A method of modulating an immune response of an individual having a transplanted organ, tissue, cell or the like comprising administering an effective amount of the humanized immunoglobulin specific to B7-1, an effective amount of a humanized immunoglobulin specific to B7-2 in a carrier and administering a drug that is used to modulate the immune response of an individual having a transplanted organ, tissue, or cell, wherein the drug is selected from the group consisting of: methotrexate, rapamycin, cyclosporin, steroids, transplant salvage pathway inhibitor, IL-2 receptor antagonist, and analogs thereof, and wherein an inhibitor of the CD40 /~~or~~ CD40 ligand costimulatory interaction is not administered to the individual.

155-160. (Canceled)